GregoryHReamanMD
Pediatric Hematology & Oncology • Washington, DCAssociate Director Office of Hematology and Oncology Products U.S. FDA
Dr. Reaman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
111 Michigan Ave NW
Washington, DC 20010Phone+1 202-884-2140
Education & Training
Loyola Medicine MacNeal HospitalInternship, Transitional Year, 1973 - 1974
Loyola University Chicago Stritch School of MedicineClass of 1973
Certifications & Licensure
MD State Medical License 1977 - 2025
DC State Medical License 1979 - 2024
VA State Medical License 1988 - 2012- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Fellow (FASCO) American Society of Clinical Oncologists, 2010
Clinical Trials
- Penicillin Prophylaxis in Sickle Cell Disease (PROPS) Start of enrollment: 1983 Aug 01
- Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia Start of enrollment: 2008 Mar 24
Publications & Presentations
PubMed
- 344 citationsAssociation of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.Donald A. Berry, Shouhao Zhou, Howard R. Higley, Lata Mukundan, Shuangshuang Fu
JAMA Oncology. 2017-07-13 - 22 citationsPatient Reported Outcomes in Pediatric Cancer Registration Trials: A U.S. Food and Drug Administration Perspective.Meena N Murugappan, Bellinda L King-Kallimanis, Gregory H. Reaman, Vishal Bhatnagar, Erica G. Horodniceanu
Journal of the National Cancer Institute. 2021-04-30 - 2 citationsChildhood cancer data initiative: Status report.Subhashini Jagu, Elaine R Mardis, Mary F Wedekind, Brigitte C Widemann, Rena K Kingery
Pediatric Blood & Cancer. 2024-02-01
Press Mentions
- Gregory Reaman Named Scientific Director of NCI’s Childhood Cancer Data InitiativeNovember 11th, 2022
- Cancer Is the Leading Cause of “Death from Disease” in Children. Here’s WhyDecember 3rd, 2021
- Better CNS Control in Children with ALL: ‘Goldilocks’ ApproachAugust 9th, 2021
- Join now to see all
Grant Support
- Targeted Therapies For Childhood Acute Lymphoblastic LeukemiaNational Cancer Institute2009
- Support For Human Specimen Banking In Nci-Supported Cancer Clinical TrialsNational Cancer Institute2007–2009
- Children'S Oncology Group Chair'S GrantNational Cancer Institute2003–2009
- Human Specimen Banking In Nci-Supported Cancer ClinicalNational Cancer Institute2005–2006
- COG - Foreign AccrualNational Cancer Institute2005
- Re-Engineering The Clinical Research EnterpriseDivision Of Epidemiology And Clinical Applications2004
- COG Foreign AccrualNational Cancer Institute2003–2004
- Pediatric Oncology GroupNational Cancer Institute2001–2002
- Intergroup Rhabdomyosarcoma StudyNational Cancer Institute2001–2002
- Childrens Cancer Group Chairmans AwardNational Cancer Institute2001–2002
- Childrens Cancer GroupNational Cancer Institute1999–2001
- Pediatric Phase I Trials Of Cytotoxic &Biologic AgentsNational Cancer Institute1996–2000
- Cancer In ChildrenNational Cancer Institute1995–1998
- Trials Of Cyotoxic And Biologic AgentsNational Cancer Institute1995
- Pediatric Phase I Trials Of Cyotoxic &Biologic AgentsNational Cancer Institute1994
- Cancer In ChildrenNational Cancer Institute1994
- Pediatric Phase I Trials Of Cyotoxic And Biologic AgentsNational Cancer Institute1992–1993
- Children'S Cancer Study GroupNational Cancer Institute1987–1993
- Childrens Cancer Study GroupNational Cancer Institute1991
- Anti-Gd3 Monoclonal Antibody Therapy Of T-Cell AllNational Cancer Institute1990–1991
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
